Nanexa shares jump 150% after deal with Ozempic maker
Shares of Swedish biotech company Nanexa surged on Friday after it announced a major deal with Novo Nordisk. The agreement, worth up to $1.33 billion, covers the development of long-acting treatments for obesity, type 2 diabetes and other cardiometabolic conditions.
As CNBC reported, Nanexa shares jumped more than 150% at the open in Stockholm. The gain later eased to around 114%. The stock moved close to its all-time high from November 2015.
Novo Nordisk gains access to Nanexa technology
Under the agreement, Novo Nordisk will receive exclusive rights to use Nanexa’s PharmaShell technology in up to five development programs. The platform coats drug particles with an ultra-thin inorganic layer that helps control how quickly the active ingredient is released.
The companies aim to develop treatments that could be administered once a month or even once a quarter. Novo Nordisk currently makes popular drugs including Wegovy and Ozempic.
Nanexa is eligible to receive around $700 million upfront, as well as additional payments tied to development and regulatory milestones. The agreement also includes royalties on future product sales.
For a small company like Nanexa, the deal is especially significant. Its revenue for all of 2025 was about $3.9 million, up 48.4% from the previous year.
Nanexa Chairman Göran Ando said the agreement will significantly strengthen the company’s financial position and allow it to expand the use of PharmaShell into other therapeutic areas. CEO David Westberg added that Nanexa will be able to advance more of its own programs toward clinical testing.
What Nanexa is known for
Nanexa is a Swedish pharmaceutical company based in Uppsala that focuses on long-acting drug formulations. Its key technology is the PharmaShell platform, which coats drug particles with an ultra-thin layer and allows the active ingredient to be released gradually.
Nanexa already works not only on its own drug programs but also with major pharmaceutical companies. In late 2025, it signed a licensing agreement with Moderna worth up to $500 million, and in 2026 it reported results from the development of a semaglutide formulation that could potentially be administered once per quarter.
Novo Nordisk shares fell nearly 7% on Monday.
Latest Novo Nordisk News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
